Key Takeaways PLSE partners to start a clinical study using the nPulse technology for papillary thyroid microcarcinoma.The FDA grants the IDE application for an early trial, enrolling 30 patients in 2026.The alliance expands the PLSE's clinical breakthrough in non-thermal soft-tissue ablation.Pulse Biosciences, Inc. (PLSE)  announced that it initiated a research collaboration with The University of Texas MD Anderson Cancer Center to test its nPulse technology — Vybrance — for treating malignant thyroid tumo ...